Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESPIRATIO
2024-512621-88-00Phase 2Completed
- Sponsor
- Dompé
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial in acute respiratory distress syndrome (ARDS) comparing Reparixin + standard of care with Placebo + standard of care (2 arms). Primary endpoints: Change in oxygenation index (OI) from baseline to day 7 of treatment and Ventilator-free days at day 28. Started Jul 2024; status: completed.
02
Drugs
reparixin
03
Conditions
acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on 2024-512621-88-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512621-88-00.